{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"15","upperLimit":"68.4","value":"30.5"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"20"}],"units":"Participants"}],"description":"International Myeloma Working Group Uniform Response Criteria was used","dispersionType":"Full Range","groups":[{"description":"Patients receive clarithromycin PO BID and dexamethasone PO once a week. Treatment with clarithromycin and dexamethasone continues for up to 1 year in the absence of disease progression or unacceptable toxicity. Patients also receive lenalidomide PO QD on days 1-14. Courses with lenalidomide repeat every 21 days in the absence of disease progression or unacceptable toxicity. Lenalidomide is taken 4 hours or more after last dose of daily clarithromycin.\n\nNOTE: \\*After one year of treatment, dexamethasone is tapered for an additional 4 weeks.\n\nClarithromycin: Given PO\n\nDexamethasone: Given PO\n\nLenalidomide: Given PO","id":"OG000","title":"Treatment (Clarithromycin, Dexamethasone, Lenalidomide)"}],"paramType":"MEDIAN","populationDescription":"Measured among the 20 patients who progressed","reportingStatus":"POSTED","timeFrame":"Up to 10.25 years","title":"Time to Disease Progression","type":"PRIMARY","unitOfMeasure":"months"}